{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:19:28Z","timestamp":1790792368407,"version":"4.1.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"Importance<\/jats:title>In spite of the effectiveness of endocrine therapy plus cyclin-dependent kinase (CDK) 4\/6 inhibitors as the first-line treatment for estrogen receptor (ER)-positive, erb-b2 receptor tyrosine kinase 2 (ERBB2<\/jats:italic> [formerly HER2<\/jats:italic>\/neu<\/jats:italic>])-negative (ER+\/ERBB2<\/jats:italic>\u2212) metastatic breast cancer (MBC), patients eventually develop resistance, and eventually most will receive chemotherapy. The METEORA-II trial compared a metronomic all-oral treatment with intravenous (IV) chemotherapy.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the efficacy of the oral vinorelbine plus cyclophosphamide plus capecitabine (VEX) regimen vs weekly IV paclitaxel among patients with ER+\/ERBB2<\/jats:italic>\u2212 MBC who are candidates for chemotherapy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This phase 2 randomized clinical trial including 140 women 18 years and older (randomized 1:1) with ER+\/ERBB2<\/jats:italic>\u2212 MBC was carried out from September 13, 2017, to January 14, 2021 at 15 centers in Italy. Eligible patients could have received 1 prior line of chemotherapy for MBC and\/or 2 lines of endocrine therapy (including CDK4\/6 inhibitors).<\/jats:p><\/jats:sec>Interventions<\/jats:title>In 4-week cycles, patients received either metronomic oral VEX or weekly IV paclitaxel.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was investigator-assessed time to treatment failure (TTF) defined as the interval between the date of randomization to the end of treatment (because of disease progression or lack of tolerability or because further trial treatment was declined). Secondary end points included progression-free survival (PFS), overall survival (OS), and disease control rate (complete or partial response or stable disease lasting for at least 24 weeks).<\/jats:p><\/jats:sec>Results<\/jats:title>In total, 133 patients received either VEX (n\u2009=\u200970) or paclitaxel (n\u2009=\u200963) in 4-weekly cycles. The median age was 61 (range, 30-80) years. The VEX treatment significantly prolonged TTF vs paclitaxel (hazard ratio [HR],\u20090.61; 95% CI, 0.42-0.88; P<\/jats:italic>\u2009=\u2009.008), median TTF was 8.3 (95% CI, 5.6-11.1) months for VEX vs 5.7 (95% CI, 4.1-6.1) months for paclitaxel, and the 12-month TTF was 34.3% for VEX vs 8.6% for paclitaxel. The median PFS was 11.1 (95% CI, 8.3-13.8) months vs 6.9 (95% CI, 5.4-10.1) months favoring VEX (HR,\u20090.67; 95% CI, 0.46-0.96, P<\/jats:italic>\u2009=\u2009.03). The 12-month PFS was 43.5% for VEX vs 21.9% for paclitaxel. No difference in OS was found. The TF event for 55.6% of patients was progression of disease; for 23% it was AEs. More patients assigned to VEX had at least 1 grade 3 or 4 targeted adverse event (VEX, 42.9%; 95% CI, 31.1%-55.3% vs paclitaxel, 28.6%; 95% CI, 17.9%-41.3%), but essentially no alopecia.<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>This randomized clinical trial found significantly prolonged TTF and PFS for oral VEX but no improvement in OS compared with intravenous paclitaxel, despite increased but still manageable toxic effects. The VEX regimen may provide more prolonged disease control than weekly paclitaxel for ER+\/ERBB2<\/jats:italic>\u2212 MBC.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02954055<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.2150","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T15:07:35Z","timestamp":1689260855000},"page":"1267","source":"Crossref","is-referenced-by-count":39,"title":["Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor\u2013Positive, ERBB2<\/i>-Negative Metastatic Breast Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Elisabetta","family":"Munzone","sequence":"first","affiliation":[{"name":"Division of Medical Senology, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith M.","family":"Regan","sequence":"additional","affiliation":[{"name":"IBCSG Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Perrino Hospital, ASL Brindisi, Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Montagna","sequence":"additional","affiliation":[{"name":"Division of Medical Senology, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Orlando","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Perrino Hospital, ASL Brindisi, Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Shi","sequence":"additional","affiliation":[{"name":"IBCSG Statistical Center, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Campadelli","sequence":"additional","affiliation":[{"name":"Faenza Hospital \u201cdegli Infermi,\u201d Oncology, Faenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gianni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ospedale Infermi, AUSL Della Romagna, Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Palleschi","sequence":"additional","affiliation":[{"name":"Department of Oncology, IRCCS, Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori,\u201d Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Bengala","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medical Oncology, Department of Oncology, Azienda USL Toscana, Misericordia Hospital, Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[{"name":"Women\u2019s Cancer Center, Azienda Socio-Sanitaria Territoriale di Cremona and University of Trieste, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Collov\u00e0","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, ASST Ovest Milanese Legnano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano, National Cancer Institute, IRCCS, Aviano, Italy"},{"name":"Department of Medicine, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cretella","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Azienda Sanitaria Dell\u2019Alto Adige, Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Chini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruepp","sequence":"additional","affiliation":[{"name":"ETOP IBCSG Partners Foundation, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[{"name":"ETOP IBCSG Partners Foundation, Bern, Switzerland"},{"name":"Peter MacCallum Cancer Centre, Division of Cancer Research, The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[{"name":"Division of Medical Senology, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy"},{"name":"ETOP IBCSG Partners Foundation, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Breast Cancer Study Group (IBCSG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Leo","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf A","family":"Stahel","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aebi","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Gelber","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"McGregor","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Hiltbrunner","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Achille","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Carrer-Wagner","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Celotto","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Comune","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Gasca","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roswitha","family":"Kammler","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Pfister","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Roschitzki","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rugiati","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Schneider","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Schroeder","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Troesch","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Bouzan","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrina","family":"Farah","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoxin","family":"Sun","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Shaw","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Blacher","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"King","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Mundy","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorene","family":"Polizzi","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Greco","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolyn","family":"Scott","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Starkweather","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Ghisini","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Masetti","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Amaducci","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Pinotti","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Donadio","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[{"name":"for the International Breast Cancer Study Group (IBCSG)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"cbr230011r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"cbr230011r2","author":"Cardoso","year":"2012"},{"issue":"6","key":"cbr230011r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100332","article-title":"Systematic review and meta-analysis of post-progression outcomes in ER+\/HER2- metastatic breast cancer after CDK4\/6 inhibitors within randomized clinical trials.","volume":"6","author":"Munzone","year":"2021","journal-title":"ESMO Open"},{"key":"cbr230011r4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.canlet.2017.01.027","article-title":"Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: a phase II trial.","volume":"400","author":"Montagna","year":"2017","journal-title":"Cancer Lett"},{"key":"cbr230011r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"6","key":"cbr230011r6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/oncolo\/oyac075","article-title":"Systemic therapies following progression on first-line CDK4\/6-inhibitor treatment: analysis of real-world data.","volume":"27","author":"Martin","year":"2022","journal-title":"Oncologist"},{"issue":"9","key":"cbr230011r7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","article-title":"Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines.","volume":"86","author":"Talbot","year":"2002","journal-title":"Br J Cancer"},{"issue":"34","key":"cbr230011r8","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","article-title":"Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.","volume":"29","author":"Stockler","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"cbr230011r9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1634\/theoncologist.2011-0281","article-title":"Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.","volume":"17","author":"O\u2019Shaughnessy","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"cbr230011r10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10549-016-4009-3","article-title":"Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.","volume":"160","author":"Cazzaniga","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"cbr230011r11","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.3390\/jcm11164710","article-title":"Metronomic chemotherapy for metastatic breast cancer treatment: clinical and preclinical data between lights and shadows.","volume":"11","author":"Cazzaniga","year":"2022","journal-title":"J Clin Med"},{"key":"cbr230011r12","author":"Pasquier","year":"2010"},{"issue":"2","key":"cbr230011r13","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000285","article-title":"Global cancer control: responding to the growing burden, rising costs and inequalities in access.","volume":"3","author":"Prager","year":"2018","journal-title":"ESMO Open"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2807037\/jamaoncology_munzone_2023_br_230011_1695221933.79691.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T18:01:53Z","timestamp":1695319313000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2807037"}},"subtitle":["Final Results From the Phase 2 METEORA-II Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.2150","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}